


New Hampshire COVID-19 Education and Childcare Partner Call

May 4, 2022




Education and Childcare Partner Call Schedule

- Date of next (and final) call/webinar is on **Wednesday 6/1** from 3:30-4:30 pm
- Webinar/call information:
 - Zoom link: <https://nh-dhhs.zoom.us/j/98062195081>
 - Webinar ID: 980 6219 5081
 - Passcode: 197445
 - Telephone: 646-558-8656

General COVID-19 Updates

Current CDC COVID-19 Community Levels




https://covid.cdc.gov/covid-data-tracker/#county-view?list_select_state=all_states&list_select_county=all_counties&data-type=CommunityLevels

Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022

- National commercial lab: cross-sectional seroprevalence study
- Blood samples from the 50 U.S. states, D.C., and Puerto Rico were tested for anti-nucleocapsid (anti-N) antibodies
 - Antibodies produced in response to infection NOT vaccination (vaccination produces antibodies against the spike protein)
 - Included persons with any detectable antibody levels on qualitative testing
- Testing occurred at 4-week intervals from Sept 2021 – Feb 2022

FIGURE. Seroprevalence of infection-induced SARS-CoV-2 antibodies,* by age group — United States, September 2021–February 2022



* Error bars represent 95% CIs at each time point.

Vaccination Is Important After Infection

- Detection of antibodies (seropositivity) does NOT mean a person is protected from future COVID-19
- Vaccination remains the safest and most effective strategy for preventing SARS-CoV-2 infection and associated complications
- Even people who are previously infected should be vaccinated against COVID-19
 - Multiple studies have shown that “hybrid immunity” offers the highest levels of protection against COVID-19

Hospitalizations of Children Aged 5–11 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022

- COVID-NET conducts surveillance for COVID-19 associated hospitalizations in 99 counties across 14 U.S. states (includes about 10% of U.S. population)
- Study analyzed COVID-19 hospitalizations in children 5-11 years of age from March 2020 – February 2022
- Compared different variant predominant time periods

COVID-19 can make some children very sick

Among nearly 400 **children ages 5–11 years** hospitalized with COVID-19 during the first few months of Omicron:*



3 in 10
had NO underlying conditions

9 in 10

were
unvaccinated



2 in 10
required ICU care

**Protect all eligible children by
keeping their vaccinations up to date**




* Dec 19, 2021—Feb 28, 2022

bit.ly/MMWR7116

APRIL 19, 2022

MMWR

Pandemic Response Changes Over Time



* “End” indicates a formal end to the pandemic and public health’s emergency response, not an end to circulation of SARS-CoV-2

The Most Important and Effective Strategy: COVID-19 Vaccination

- Promote vaccination to ensure children and staff are [Up To Date on All Recommended COVID-19 Vaccines](#) (including boosters)
- Everybody 5 years of age and older is recommended to be vaccinated against COVID-19 with a primary series
- Everybody 12 years of age and older is also recommended to receive a booster after the recommended elapsed time interval
 - A booster dose is very important to have the highest protection against COVID-19, especially with the emergence of newer variants
 - Certain at-risk populations are eligible for a second booster starting at least 4 months after completing their first booster

Pfizer and BioNTech Submit Application for U.S. Emergency Use Authorization for a COVID-19 Vaccine Booster Dose in Children 5 Through 11 Years of Age

Tuesday, April 26, 2022 - 04:30pm

- 10 mcg booster
- No new safety signals
- Study “demonstrated a strong immune response in this age group following a booster dose...”

Core Prevention Strategies

- Increase and maximize [ventilation in buildings](#)
- Promote frequent hand hygiene and teach good respiratory etiquette
- Persons with new/unexplained [symptoms of COVID-19](#) should stay home and test for COVID-19 (antigen tests are appropriate)
- [Isolation and quarantine](#)
 - Isolation: for people who test positive for COVID-19 or who have symptoms of COVID-19 while awaiting test results
 - Quarantine: For household contacts who are unvaccinated or NOT “up to date” on receiving all recommended COVID-19 vaccine doses

Additional Prevention Strategies

- Face mask use:
 - Face masks are effective
 - People who are immunocompromised or who want additional protection can choose to wear face masks in indoor public locations (use based on individual choice and assessment of risk)
- [Cleaning and disinfection:](#)
 - Routine cleaning
 - Disinfection if a person with COVID-19 is present in a room
- Asymptomatic screening testing:
 - Routine screening testing
 - Screening after a known or potential exposure
 - Testing resources remain available

Covid-19 Testing Resources For Schools



Overview

- ▶ **Vault Medical Services (at-home PCR tests)**
 - Direct-to-consumer model
 - Community Distribution model

- ▶ **BinaxNOW Point-of-Care**

- ▶ **Over-the-counter (OTC) antigen tests**

- ▶ **Community Testing Options**

Vault Medical Services

▶ Direct-to-consumer

- Free at-home PCR tests are still available
 - Saliva-based test
 - Kit includes specimen collection tube, instructions, and postage-paid UPS envelope
- A link to order these can be found on the NH Covid-19 website [here](#), as well as a direct link to the Vault website [here](#)

▶ Community distribution points

- Schools may order PCR test kits using this [link](#) for free
- Distribute tests to community members

BinaxNOW Antigen Tests

- ▶ **Schools may order BinaxNOW Covid-19 antigen tests**
 - A CLIA ID & medical direction are required to order and use these tests
 - SASS program fulfills the medical direction and CLIA ID requirements for participating schools
 - **Must be used on-site**
 - Because of the type of antigen test, these tests must be used at the school and should not be sent home with staff or students
 - **Supplies are based upon availability**
 - 6 boxes (40 tests/box) are available per school monthly
 - Click [here](#) to order tests



Flowflex Over-the-counter (OTC) Covid-19 Tests

▶ OTC antigen tests for schools and daycares

- Distribution program is temporarily delayed
 - *Orders already submitted will be honored when the distribution program resumes*
- Anticipate re-opening this program the week of May 23rd

▶ Ordering Process

- Use this [link](#) to order free tests
 - Orders will be accepted based upon supply availability
- Pick-up location: DHHS Warehouse, Concord
 - A DHHS staff member will coordinate an appointment to pick-up these tests



Community Testing Locations

- ▶ Community testing locations
 - Covid-19 testing is available at traditional healthcare locations
 - Visit the NH Covid-19 website for a [list](#) of available testing resources

COVID-19 Vaccine for Children 6 Months Through 4 Years of Age

Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age

Friday, February 11, 2022 - 01:30pm

“Given that the study is advancing at a rapid pace, the companies will wait for the three-dose data... The companies expect to have three-dose protection data available in early April.”

<https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-rolling-submission>

Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 Years Has Successfully Met Its Primary Endpoint

3/23/2022

- Two 25 µg doses of mRNA-1273 in participants 6 months to under 6 years met primary endpoint with robust neutralizing antibody titers similar to adults mRNA-1273 was generally well tolerated in this age group
- Although not a primary endpoint, statistically significant vaccine efficacy was observed during the Omicron wave that was consistent with the lower two-dose effectiveness against Omicron seen in adults
- Moderna is moving forward with global regulatory submissions for mRNA-1273 for primary vaccination of children 6 months to under 6 years of age
- Additionally, Moderna has initiated a submission to the FDA for emergency use authorization of mRNA-1273 in children 6 to under 12 years of age; mRNA-1273 is approved for use in this age group in Europe, Canada and Australia

<https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-its-COVID-19-Vaccine-Phase-23-Study-in-Children-6-Months-to-Under-6-Years-Has-Successfully-Met-Its-Primary-Endpoint/default.aspx>

Moderna Announcement (3/23/2022)

- Two 25 mcg doses in children provided “similar immunogenicity” (non-inferiority criteria met) compared to two 100 mcg doses in adults 18-25 years of age
- Omicron predominated during KidCOVE study – vaccine efficacy (VE) at preventing infection was statistically significant and consistent with adult 2-dose VE data
 - VE in children 6 months – 2 years: 44%
 - VE in children 2 – 6 years: 38%
- No severe COVID-19 cases were observed preventing estimates of VE against hospitalizations or deaths
- No safety concerns
- Moderna is evaluating VE of a “booster dose” for all pediatric populations



NEWS RELEASE

Moderna Files for Authorization of Its COVID-19 Vaccine in Young Children Six Months to Under Six Years of Age

4/28/2022

https://s29.q4cdn.com/435878511/files/doc_news/Moderna-Files-for-Authorization-of-Its-COVID-19-Vaccine-in-Young-Children-Six-Months-to-Under-Six-Years-of-Age-2022.pdf



Coronavirus (COVID-19) Update: FDA Announces Tentative Advisory Committee Meeting Schedule Regarding COVID-19 Vaccines

[f Share](#) [t Tweet](#) [in LinkedIn](#) [✉ Email](#) [🖨 Print](#)

For Immediate Release: April 29, 2022

Today, the U.S. Food and Drug Administration is announcing its plans to hold virtual meetings of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) in anticipation of complete submissions of emergency use authorization (EUA) requests in the coming months that have been publicly announced by COVID-19 vaccine manufacturers.

It is important to note that the dates below are tentative as none of the submissions are complete. The agency understands the urgency to authorize a vaccine for age groups who are not currently eligible for vaccination and will work diligently to complete our evaluation of the data. Should any of the submissions be completed in a timely manner and the data support a clear path forward following our evaluation, the FDA will act quickly and anticipates convening the following VRBPAC meetings:

- On June 7, FDA intends to convene VRBPAC to discuss an EUA request for a COVID-19 vaccine manufactured by Novavax to prevent COVID-19 in individuals 18 years of age and older.
- On June 8, 21 and 22, the FDA has held dates for the VRBPAC to meet to discuss updates to the Moderna and Pfizer-BioNTech EUAs for their COVID-19 vaccines to include younger populations. As the sponsors complete their submissions and the FDA reviews that data and information, it will provide additional details on scheduling of the VRBPAC meetings to discuss each EUA request.
- On June 28, the FDA plans to convene the VRBPAC to discuss whether the SARS-CoV-2 strain composition of COVID-19 vaccines should be modified, and if so, which strain(s) should be selected for Fall 2022. This meeting is a follow-up to the April 6 VRBPAC meeting that discussed general considerations for future COVID-19 vaccine booster doses and the strain composition of COVID-19 vaccines to further meet public health needs.

COVID-19 Vaccination for Children 6 Months Through 4 Years of Age

- COVID-19 vaccines for children under the age of 5 years may not be available until summer
- Vaccination for this younger age group will occur primarily through a child's primary care provider or medical home
- If there are resources we can develop that might be helpful for you (e.g., childcare partners) to help promote vaccination, please let us know (comment in the webinar's Chat box)

Q&A

Education and Childcare Partner Call Schedule

- Date of next (and final) call/webinar is on **Wednesday 6/1** from 3:30-4:30 pm
- Webinar/call information:
 - Zoom link: <https://nh-dhhs.zoom.us/j/98062195081>
 - Webinar ID: 980 6219 5081
 - Passcode: 197445
 - Telephone: 646-558-8656